Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758673 | 0.79 | FOLH1 (0.49) | ELANETSHRTRPA1 | |
| SCHEMBL3681679 | 0.79 | NPSR1 (0.41) | LMNATSHRSMN1; SMN2NPSR1PDK2 | |
| SCHEMBL1549947 | 0.74 | LMNA (0.47) | POLBLMNATSHRNPSR1CNR2 | |
| SCHEMBL2762867 | 0.72 | BCAT2 (0.51) | LMNATSHRSMN1; SMN2NPSR1PDK2 | |
| SCHEMBL25936797 | 0.72 | KMT2A (0.44) | TSHRSMN1; SMN2NPSR1KDM2B | |
| SCHEMBL9817577 | 0.71 | TRPA1 (0.42) | ELANETRPA1 | |
| SCHEMBL3678742 | 0.71 | ELANE (0.34) | POLBLMNAELANETSHRNPSR1 | |
| SCHEMBL14862584 | 0.70 | SLC6A2 (0.47) | LMNASMN1; SMN2TRPA1 | |
| SCHEMBL5819855 | 0.68 | FOLH1 (0.48) | LMNATSHR | |
| SCHEMBL2996249 | 0.68 | AKR1C3 (0.46) | POLBNPSR1KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2289867-A2 | A process for producing 4-(4-halo-1-oxybutyl)-alpha,alpha-dimethylbenzene acetic acid or alkyl esters thereof | Jubilant Organosys Limited (IN) | 2011-03-02 | — | — | EP | disclosed |
| US-6903232-B2 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-α, α-dimethylphenylacetic acid | AUROBINDO PHARMA LTD. (IN) | 2005-06-07 | — | — | US | disclosed |
| US-20040077900-A1 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid | AUROBINDO PHARMA LIMITED (IN) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077900-A1 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid | CMA1, HRH1, HRH2 | ABL1 852/4885POLB 3536/4885LMNA 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.